-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V3BkKfPnF1FezRbyb0OWl7wIohRTowZW6qZ5y4HHcZtnNyPgIIAtDc0kYlMaarqN zwevH8tbNzph7G8igTqOUA== 0000927016-95-000177.txt : 19951020 0000927016-95-000177.hdr.sgml : 19951020 ACCESSION NUMBER: 0000927016-95-000177 CONFORMED SUBMISSION TYPE: 10-C PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19951018 FILED AS OF DATE: 19951019 SROS: NONE FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-C SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 95581689 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-C 1 FORM 10-C SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-C REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ INTERDEALER QUOTATION SYSTEM FILED PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 13A-17 OR 15D-17 THEREUNDER GENZYME CORPORATION - -------------------------------------------------------------------------------- (Exact name of issuer as specified in charter) One Kendall Square, Cambridge, Massachusetts 02139 - -------------------------------------------------------------------------------- (Address of principal executive offices) Issuer's telephone number, including area code: (617) 252-7500 -------------------------------- I. CHANGE IN NUMBER OF SHARES OUTSTANDING Indicate any change(increase or decrease) of five percent or more in the number of shares outstanding: 1. Title of security: General Division Common Stock, $0.01 par value per share --------------------------------------------------------- 2. Number of shares outstanding before the change: 28,452,617 shares ---------------------------- 3. Number of shares outstanding after the change: 31,327,617 shares ----------------------------- 4. Effective date of change: October 18, 1995 -------------------------------------------------- 5. Method of change: Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acquisition of stock for treasury, etc): Public Offering ------------------------------------------------------------------------- Give brief description of transaction: On October 18, 1995, Genzyme Corporation ---------------------------------------- issued 2,875,000 shares of its General Division Common Stock in a public - ------------------------------------------------------------------------------- offering registered under the Securities Act of 1933, as amended. - -------------------------------------------------------------------------------- II. CHANGE IN NAME OF ISSUER 1. Name prior to change: ------------------------------------------------------- 2. Name after change: ---------------------------------------------------------- 3. Effective date of charter amendment changing name: -------------------------- 4. Date of shareholder approval of change, if required: ------------------------ Date: October 19, 1995 /s/ David J. McLachlan ---------------- ----------------------------------------- David J. McLachlan, Senior Vice President, Finance and Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----